Valitacell have an active and growing pipeline of products and services under development. Many of Valitacell's products are the result of successful partnerships with companies and research institutions around the world, including the Advanced Biomanufacturing Centre at The University of Sheffield, and the Regenerative Medicine Institute of Ireland at National University of Ireland Galway. Current research programmes include:
ValitaCUSTOM - Customised Product Quantification Assays
We have demonstrated the utility of using our Fluoresence Polarisation technology to measure the concentration of a variety of products. We are at an advanced stage of providing this to end-users as a customised assay development service so that users can benefit from customised, high-throughput and cost effective assays for non-MAb products.
ValitaPIX - In-Line, Dynamic IgG Measurement
ValitaPIX allows the measurement of a clones ability to sequentially produce the desired product, without any removal of sample to off-line analytical platforms.
ValitaHCP - Host Cell Protein Quantification
We are working with partners to validate a high-throughout assay to measure Host Cell protein (HCP) using our Fluoresence Polarisation technology. The ValitaHCP assay allows users to rapidly quantify HCP.
ValitaDESIGN - Media Feed Optimisation By Design
Offering complete, daily control of media & feed strategy is of paramount importance, ValitaDESIGN is a high-throughput media development tool for enhancing titer production and cellular performance. The technology is based on Valitacell's ChemEffect platform for easy, rapid media optimisation for each individual product.
ValitaSTEM - Autologous Batch Review
We have recently initiated a programme of research, analogous to our Chemstress technology on CHO cells, to design a manufacturing analytic which is based on a tailored challenge to the MSC-cell receptome. This challenge will be plate based and utilises the knowledge gained from the small molecule stressors utilised on the ChemStress plate. The initial goal is to examine the product's utility to define entry criterion for autologous batches before committing to expand.